Elaine Chen
@elaineywchen.bsky.social
2.6K followers 130 following 51 posts
Reporter @statnews.com covering drugs and the biopharma industry | signal: elaineywchen.70
Posts Media Videos Starter Packs
Reposted by Elaine Chen
jonathanwosen.bsky.social
I'm a science journalist for @statnews.com looking to talk with folks who applied to biomedical Ph.D. programs and had offers rescinded earlier this year. What have you been up to since then? You can reach me at [email protected] or via Signal (username jwosen.27). #journorequest
elaineywchen.bsky.social
Latest: A race to develop a new class of narcolepsy drugs could not only transform treatment for patients with the rare sleep disorder, but also many people with common health conditions like Alzheimer's and depression who struggle to stay awake
Drugmakers are racing to help patients stay awake — and could also make billions
A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with other conditions that cause them to struggle to stay awake.
www.statnews.com
elaineywchen.bsky.social
From #ADA25: Full results suggest Novo's CagriSema is comparable to Lilly’s Zepbound on safety and efficacy

Weight loss looks to be plateauing at the end of late-stage studies, raising Qs around how much more weight patients can lose on the drug
Novo Nordisk’s amylin obesity drug keeps performing like Zepbound
Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.
www.statnews.com
elaineywchen.bsky.social
Latest from #ADA25: Novo's injectable amycretin showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side effects raise questions about which dose Novo will pursue going forward
Full data on Novo Nordisk’s new amylin drug raise dosing questions
Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will pursue.
www.statnews.com
Reposted by Elaine Chen
alexhogan.bsky.social
New video- my new @statnews.com colleague @chelseacirruzzo.bsky.social and I chat about RFK Jr.'s dismissal of all the members of ACIP, CDC's vaccine advisory board. Also I'm going to be doing a video every week now so please wish me luck (and like & subscribe plz) youtu.be/brVDswDpaeQ
Did RFK Jr. break a promise he made to GOP Senator?
YouTube video by STAT
youtu.be
elaineywchen.bsky.social
Novo also invested much less in R&D than competitor Eli Lilly

It tended to advance one candidate at a time, rather than simultaneously advance multiple candidates at once to see what stuck, one former employee said
www.statnews.com/2025/06/05/n...
elaineywchen.bsky.social
LATEST: A conservative culture cost Novo Nordisk its lead in the obesity drug race, former employees told me

It wanted to tread carefully as the first mover in the space, and its belief in Ozempic/Wegovy blinded it to other candidates, they said
A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say
Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.
www.statnews.com
Reposted by Elaine Chen
isabellacueto.bsky.social
NEW: How RFK Jr. goes about solving the chronic disease epidemic depends on his top concerns. Here, we break down the nation's health into 9 "priorities" — using original data analysis you can't find elsewhere! — and let you choose yours. W/ @jaspar.bsky.social:

www.statnews.com/2025/05/20/k...
RFK Jr. declared war on chronic disease. First comes the battle over priorities
How would you solve the chronic disease epidemic? Here's STAT's extensive new data analysis, and nine ways to tackle the problem.
www.statnews.com
elaineywchen.bsky.social
The explosion of compounded GLP-1 offerings is ending, and many patients are left with no good options.

Telehealth companies and compounders are pursuing workarounds that may be riskier. At the same time, patients still can't afford the branded drugs. w/ @katiepalmer.bsky.social
The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from
www.statnews.com
Reposted by Elaine Chen
mmolteni.bsky.social
WaPo has the numbers on those NIH advisory board purges @jasonmast.bsky.social and I first reported on last month.

Six percent of White males who serve on boards were fired, compared with half of Black and Hispanic females and one-quarter of all females, according to an analysis by board chairs.
washingtonpost.com
Thirty-eight of 43 experts cut last month from the boards that review the science and research that happens in laboratories at the National Institutes of Health are female, Black or Hispanic, according to an analysis by the chairs of a dozen of the boards.
Women, minorities fired in purge of NIH science review boards
Scientists, with expertise in fields that include mental health, cancer and infectious disease, typically serve five-year terms and were not given a reason for their dismissal.
www.washingtonpost.com
Reposted by Elaine Chen
alexhogan.bsky.social
What do the Trump administrations tariffs mean for the pharmaceutical industry? New short vid @statnews.com h/t to my STAT colleagues @elaineywchen.bsky.social and Ed Silverman
Reposted by Elaine Chen
isabellacueto.bsky.social
HHS workers affected by today's announcement/ RIF: Tell us what's going on! You can do so confidentially/anonymously through this form. I'm also at isabellacueto.03 on Signal, or send a DM.

www.statnews.com/2025/03/27/h...
Are you affected by the HHS cuts and restructuring?
HHS is set to cut 10,000 jobs and consolidate divisions — have you been affected? @statnews would like to hear from you.
www.statnews.com
Reposted by Elaine Chen
bobjherman.bsky.social
Eli Lilly's obesity and diabetes drugs are paying off for top executives. CEO Dave Ricks took home $114 million last year, and he and other leaders also were treated to a "leadership meeting" at last summer’s Olympics in Paris. More w/ @elaineywchen.bsky.social: www.statnews.com/2025/03/11/e...
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
www.statnews.com
elaineywchen.bsky.social
Pfizer also replaced language saying that it partners with groups that “are dedicated to championing historically underrepresented populations” and deleted a list of its partners
www.statnews.com/2025/02/27/p...
elaineywchen.bsky.social
Pfizer yesterday revised its DEI webpage to emphasize the importance of "merit," joining other companies seeking to align with the Trump administration

@jaspar.bsky.social and I laid out all the deletions and insertions in our story
www.statnews.com/2025/02/27/p...
elaineywchen.bsky.social
I echo what Emory has said and if you want to learn about promotions we have for our subscriptions or questions on how to get institutional access or on the story itself, feel free to DM
Reposted by Elaine Chen
jaspar.bsky.social
Incredible: we're reaching a point where new weight loss drugs might be *too* effective, leading to health risks. from @elaineywchen.bsky.social www.statnews.com/2025/02/20/t...
Chart showing the percent of body weight loss has increased substantially from about 5-10% in early drugs, up to 20-24% in the latest GLP drugs.
elaineywchen.bsky.social
New obesity treatments have been transformational, but the fixation on more weight loss may not be in patients' best interests, doctors say.

Rapid and extreme weight loss may lead to too much muscle loss, a weakened immune system, and other risks
www.statnews.com/2025/02/20/t...
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs.
www.statnews.com
elaineywchen.bsky.social
NEW: Patients in trials of Lilly's next-gen obesity drug tell me they think they're losing too much weight. One started skipping doses, another is making himself eat caloric foods.

This is part of what some see as a risky race for more weight loss
www.statnews.com/2025/02/20/t...
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs.
www.statnews.com